Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for liver and viral diseases, primarily nonalcoholic steatohepatitis (NASH) and chronic hepatitis B (HBV). The company operates within the biotechnology and pharmaceutical research industries, with activities centered on drug discovery, preclinical development, and clinical trials rather than commercial product sales.
The company’s core strategy has been to develop small-molecule and oligonucleotide-based therapies that target well-validated biological pathways involved in liver disease progression and viral replication. Aligos was founded in 2015 and completed its initial public offering in 2020, becoming listed on the Nasdaq under the ticker ALGS. Since inception, the company has evolved through multiple pipeline iterations, including advancement and subsequent discontinuation of certain clinical and preclinical programs following trial results and strategic reviews.
Business Operations
Aligos operates as a single-reporting-segment biotechnology company, with revenue generation historically limited to collaboration-related income rather than product sales. The company’s business model centers on internal research and development, supported by intellectual property around its therapeutic candidates, with expenditures primarily directed toward clinical trials, manufacturing of investigational drugs, and regulatory activities.
Operations are primarily based in the United States, with clinical trials conducted through third-party contract research organizations in both domestic and international locations. Aligos does not own large-scale manufacturing facilities and instead relies on external partners for clinical-grade drug production. Public disclosures indicate no material revenue-generating subsidiaries, and data on long-term commercial partnerships remains inconclusive based on available public sources.
Strategic Position & Investments
Strategically, Aligos has focused on high-unmet-need liver diseases, particularly NASH and HBV, where treatment options remain limited and regulatory pathways are complex. The company’s pipeline has included both metabolic modulators and RNA-based antiviral approaches, reflecting a diversified scientific strategy aimed at multiple disease mechanisms.
Over time, Aligos has made portfolio decisions to discontinue or pause certain development programs following clinical outcomes and capital allocation reviews. The company has not completed any transformational acquisitions and has instead prioritized internal R&D investment. As of the most recent public disclosures, information on active late-stage clinical assets and future pipeline prioritization is evolving, and some program-level details are data inconclusive based on available public sources.
Geographic Footprint
Aligos Therapeutics is headquartered in the United States, with its principal executive offices located in California. The company’s operational footprint is primarily U.S.-based, reflecting its focus on research management, regulatory strategy, and corporate functions.
Clinical development activities extend internationally through trial sites in North America, Europe, and other select regions, depending on study design and regulatory requirements. While Aligos does not maintain significant physical operations outside the U.S., its research and clinical programs have a global scope aligned with the worldwide prevalence of liver and viral diseases.
Leadership & Governance
Aligos is led by an executive team with extensive experience in biotechnology, pharmaceuticals, and clinical development, particularly in liver disease and antiviral therapeutics. Leadership emphasizes scientific rigor, disciplined capital allocation, and data-driven decision-making in pipeline development.
Key executives include:
- Lawrence Blatt, Ph.D. – Chief Executive Officer
- Peter Hurwitz – Chief Financial Officer
- Rajesh Devraj, Ph.D. – Chief Scientific Officer
- Bill Furlong, Ph.D. – Chief Development Officer
The company is governed by a board of directors composed of industry veterans and financial professionals, providing oversight on strategy, risk management, and shareholder alignment.